"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 0 | 2 |
| 1995 | 3 | 0 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 2 | 0 | 2 |
| 1998 | 2 | 2 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 1 | 3 |
| 2001 | 2 | 1 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 0 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 5 | 0 | 5 |
| 2017 | 1 | 0 | 1 |
| 2018 | 5 | 2 | 7 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 0 | 4 |
| 2021 | 4 | 0 | 4 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial. Int J Drug Policy. 2024 May; 127:104390.
-
Intraoperative Methadone Administration Is Not Associated With an Increase in Perioperative Use of Naloxone: A Retrospective Study. Anesth Analg. 2024 May 01; 138(5):1145-1147.
-
Evaluating the Association between Prenatal Care Visits and Adverse Perinatal Outcome in Pregnancies Complicated by Opioid Use Disorder. Am J Perinatol. 2024 05; 41(S 01):e2225-e2229.
-
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry. 2023 01 01; 80(1):84-92.
-
Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior. Subst Use Misuse. 2022; 57(12):1761-1771.
-
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. Eur J Clin Pharmacol. 2022 Jun; 78(6):965-973.
-
Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans. Addict Sci Clin Pract. 2022 01 31; 17(1):6.
-
Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance. Br J Pharmacol. 2022 01; 179(2):227-241.
-
Healthcare Use After Buprenorphine Prescription in a Community Emergency Department: A Cohort Study. West J Emerg Med. 2021 Sep 24; 22(6):1270-1275.
-
Switching pharmacies leads to gaps in medication possession in individuals treated with buprenorphine. J Am Pharm Assoc (2003). 2021 Sep-Oct; 61(5):589-595.